A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 268-276

  Shen, Zan ^a,b   Wong, Oscar Gee Wan ^b,d   Yao, Ru Yong ^b,c   Liang, Jun ^c   Kung, Hsiang Fu ^d   Lin, Marie C M ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c QINGDAO UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti tumor; Cocktail gene therapy; Hepatocellular carcinoma; HGFK1

Indexed keywords

ADENOASSOCIATED VIRUS VECTOR HEPATOCYTE GROWTH FACTOR KRINGLE 1 DOMAIN; ADENOVIRUS VECTOR; ADENOVIRUS VECTOR PROTEIN P53; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; PROTEIN P53; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COCKTAIL GENE THERAPY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HISTOPATHOLOGY; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TRANSGENE; TUMOR NECROSIS; TUMOR VOLUME; VIRAL GENE THERAPY;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; KRINGLES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED BUF; TUMOR SUPPRESSOR PROTEIN P53;

MUS; RATTUS;

EID: 55949123311     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.064     Document Type: Article

References (18)

1. El Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
2. Zhu A.X. Hepatocellular carcinoma: are we making progress. Cancer Invest. 21 (2003) 418-428
3. Gish R.G. Hepatocellular carcinoma: overcoming challenges in disease management. Clin. Gastroenterol. Hepatol. 4 (2006) 252-261
4. Bruix J., and Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 (2002) 519-524
5. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol. 23 (2005) 8093-8108
6. Simonetti R.G., Liberati A., Angiolini C., and Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 8 (1997) 117-136
7. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 127 (2004) S218-S224
8. Cusnir M., and Patt Y.Z. Novel systemic therapy options for hepatocellular carcinoma. Cancer J. 10 (2004) 97-103
9. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
10. Xin L., Xu R., Zhang Q., Li T.P., and Gan R.B. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem. Biophys. Res. Commun. 277 (2000) 186-190
11. Shen Z., Yang Z.F., Gao Y., Li J.C., Chen H.X., Liu C.C., Poon R.T., Fan S.T., Luk J.M., Sze K.H., Li T.P., Gan R.B., He M.L., Kung H.F., and Lin M.C. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res. 68 (2008) 404-414
12. Ogawa K., Yasumura S., Atarashi Y., Minemura M., Miyazaki T., Iwamoto M., Higuchi K., and Watanabe A. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J. Hepatol. 40 (2004) 278-284
13. Chen Y., Luk K.D., Cheung K.M., Xu R., Lin M.C., Lu W.W., Leong J.C., and Kung H.F. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther. 10 (2003) 1345-1353
14. Gao Y., Ng S.S., Chau D.H., Yao H., Yang C., Man K., Huang P.T., Huang C., Huang J.J., Kung H.F., and Lin M.C. Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther. (2008)
15. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., and Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002) 1172-1181
16. Lee T.Y., Wu H.C., Tseng Y.L., and Lin C.T. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 64 (2004) 8002-8008
17. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., Ogino K., Tanaka M., Ishikawa D., Tsukada H., Momose M., Nakayama J., and Taki T. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21 (2002) 2662-2669
18. Teodoro J.G., Evans S.K., and Green M.R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85 (2007) 1175-1186